ARCHIVES

FDA Should Delay Provenge Decision Pending Definitive Trial Results, ODAC Chairman Writes.

This article is from The Cancer Letter archive.

Vol. 33 No. 16 | April 27, 2007

Download PDF Visit The Full Archive

Related Articles

Panel Says Tamoxifen Remains Standard for Preventing Breast Cancer

May 24, 2002

At Its Launch, STAR Trial Inherits Baggage Of Its Predecessor, P-1 Tamoxifin Study

June 4, 1999

WHT Participants Get “Phase Out” Help

March 11, 1988

Cancer Policy: EMFs “Possible” Carcinogen, Panel Says; Plans Public Hearings

August 7, 1998

Conferess Ok $10.9 Bil. NIH Bidget, OAM to Get $3.5 Million

October 15, 1993

FDA Approves Xeloda For Colon Cancer; Phase III Data Not Reviewed By ODAC.

May 4, 2001